Compugen Bolsters Cancer Therapy Portfolio With New Patent

TipRanksNov 27 20:32

Compugen Expands Its Intellectual Property Portfolio With New U.S. Patent Covering Triple Combination Use Of COM902 (Reduced FC Anti-TIGIT) With Anti-PD-1 And Anti-PVRIG Antibodies

BenzingaNov 27 20:03

Roche Anti-TIGIT Therapy Fails to Extend Survival in Late-stage Lung Cancer Trial

Seeking AlphaNov 26 19:53

Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Yahoo FinanceNov 15 18:11

Truist Financial Maintains Compugen(CGEN.US) With Buy Rating

Futu NewsNov 13 20:31 · Ratings

Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript Summary

Futu NewsNov 13 04:40 · Conference Call